与 «PROSTACYCLIN»相关的英语书籍
在以下的参考文献中发现
prostacyclin的用法。与
prostacyclin相关的书籍以及同一来源的简短摘要提供其在 英语文献中的使用情境。
1
Prostacyclin and Its Receptors
This volume discusses the properties of prostacyclin receptors in the cardiovascular and nervous systems, as well as in cells involved in inflammatory reactions.
Helen Wise, Robert L. Jones, 2013
2
Cytochrome P450: Structure, Mechanism, and Biochemistry
Purification of prostacyclin synthase from bovine aorta by immunoaffinity
chromatographv. Evidence that the enzyme is a hemoprotein. J. Biol Chem. 258.
3285-3293. 1080. Hara, S., A. Miyata, C. Yokoyama, H. Inoue, R. Brugger, F.
Lottspeich ...
Paul R. Ortiz de Montellano, 2005
Platelet activation and vasoconstriction induced by TXA2 can be inhibited by
prostacyclin.215 Through increased platelet cAMP levels, prostacyclin blocks
arachidonic acid formation271 and thus prevents synthesis of prothrombotic ...
4
Drugs in Pregnancy and Lactation: A Reference Guide to Fetal ...
Varela AF, Runge A, Ignarro LJ, Chaudhuri G. Nitric oxide and prostacyclin inhibit
fetal platelet aggregation: a response similar to that observed in adults. Am J
Obstet Gynecol 1992;167:1599–604. 3. Jouppila P, Kirkinen P, Koivula A, ...
Gerald G. Briggs, Roger K. Freeman, Sumner J. Yaffe, 2011
5
Eicosanoids in Reproduction
Goodman, R. P., Killam, A. P., Brash, A. R., and Branch, R. A., Prostacyclin
production during pregnancy: comparison of production during normal
pregnancy and pregnancy complicated by hypertension, Am. J. Obstet. Gynecol,
142, 817, 1982.
6
Drugs and the Delivery of Oxygen to Tissues
Gorman, R. R., Bunting, S., and Miller, O. V., Modulation of human platelet
adenylate cyclase by prostacyclin (PCX), Prostaglandins. 13, 377, 1977. 497.
Best, L. C., Martin, T. J., Russell, R. G. G., and Preston, F. E., Prostacyclin
increases cyclic ...
7
EDHF: The Complete Story
49 Furthermore, the ability of prostacyclin to produce hyper- polarization of
smooth muscle cells depends on the membrane potential of the latter. In blood
vessels such as the uterine artery of the guinea pig, prostacyclin does not
provoke ...
Michel Feletou, Paul Vanhoutte, 2005
8
G Protein-Coupled Receptors in Health and Disease
neuropeptide release from dorsal root ganglion cultures.152 Prostacyclin analog
carbacyclin suppresses outward Kþ current in rat dorsal root ganglion.153,154 In
guinea pig nodose ganglion, prostacyclin inhibits a slow ...
9
Textbook of Pulmonary Vascular Disease
Horst Olschewski Abstract Prostacyclin was the first effective therapy for patients
with pulmonary arterial hypertension. The first experiences were reported in 1980
and the first patient with severe idiopathic pulmonary arterial hypertension ...
Jason X. -J. Yuan, Joe G.N. Garcia, Charles A. Hales, 2011
10
Kendig and Chernick's Disorders of the Respiratory Tract in ...
... in many PAH patients. Alternative forms of delivery of longer-acting
prostacyclin analogs, including subcutaneous and aerosolization, have also
been developed and may prevent (or delay) the need for parenteral prostacyclin
therapy in ...
Robert W. Wilmott, Thomas F. Boat, Andrew Bush, 2012
包含词语«PROSTACYCLIN»的新条目
找出国内和国际出版社所讨论的内容，以及词语
prostacyclin在以下新条目的上下文中是如何使用的。
United Therapeutics Corporation Reports Second Quarter 2015 …
... in the number of patients being treated, which strengthens our belief in the organic growth opportunity of our orally-administered prostacyclin analogue.". «CNNMoney, 七月 15»
Global Pulmonary Arterial Hypertension (Prostacyclin and …
The global PAH market has been segmented into prostacyclin and prostacyclin analogs, ERAs, PDE-5 inhibitors, and sGC stimulators, based on the ... «PR Newswire, 七月 15»
Analysts Views: United Therapeutics Corporation (NASDAQ:UTHR)
Its therapeutic products and product candidates include: Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor, Adcirca, Monoclonal Antibodies ... «Markets Daily, 七月 15»
Pulmonary Arterial Hypertension (PAH) Market (Prostacyclin and …
In chapter four, the global PAH market has been segmented into prostacyclin and prostacyclin analogs, endothelin receptor antagonists (ERAs), ... «MarketWatch, 七月 15»
United Therapeutics CEO Martine A. Rothblatt Sells 2592 Shares …
The Company's therapeutic products and product candidates include: Prostacyclin Analogues, the lead product is Remodulin Injection, for the treatment of ... «Dakota Financial News, 七月 15»
Analyst Price Target Update on United Therapeutics Corporation
Its therapeutic products and product candidates include: Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor, Adcirca, Monoclonal Antibodies ... «Money Flow Index, 七月 15»
Company Shares of United Therapeutics Corporation Drops by -6.76%
Its therapeutic products and product candidates include: Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor, Adcirca, Monoclonal Antibodies ... «American Trade Journal, 六月 15»
New report shares details about the pulmonary arterial hypertension …
Advanced treatment of PAH includes prostacyclin and prostacyclin analogs, phosphodiesterase-5 (PDE-5) inhibitors, endothelin receptor antagonists (ERAs) ... «WhaTech, 六月 15»
Uptravi Boost to Pulmonary Arterial Hypertension (PAH) Market to …
Prostacyclin and prostacyclin analogs were the first U.S. FDA approved drugs to be introduced in the global pulmonary arterial hypertension market. The drugs ... «Business Wire, 四月 15»
Selexipag (Uptravi) long-term outcome data in pulmonary arterial …
Dr. McLaughlin commented on the findings shared at ACC: "As the first event-driven study with a treatment targeting the prostacyclin pathway, the results ... «Yahoo Finance UK, 三月 15»
